Get daily, sector-specific newsletters packed with expert insights, fresh ideas, and new opportunities.
Subscribe to Newsletters Ipsen (IPSEY) to acquire U.S.-based Kartos Therapeutics for $450M in cash, expanding its late-stage oncology portfolio with a Phase III blood cancer therapy
Ipsen (IPSEY) said the acquisition aligns with its strategy to build a stronger late-stage oncology franchise To ensure this doesnât happen in the future, please enable Javascript and cookies in your browser